Jupiter Asset Management Ltd. Acquires 221,158 Shares of Adaptive Biotechnologies Corporation $ADPT

Jupiter Asset Management Ltd. grew its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 442.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 271,128 shares of the company’s stock after buying an additional 221,158 shares during the period. Jupiter Asset Management Ltd. owned 0.18% of Adaptive Biotechnologies worth $4,056,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. First Trust Advisors LP boosted its holdings in Adaptive Biotechnologies by 4,802.2% in the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock valued at $8,636,000 after acquiring an additional 726,184 shares in the last quarter. Peregrine Capital Management LLC bought a new stake in shares of Adaptive Biotechnologies during the 2nd quarter valued at about $8,187,000. Hillsdale Investment Management Inc. bought a new stake in shares of Adaptive Biotechnologies during the 2nd quarter valued at about $6,618,000. Cubist Systematic Strategies LLC purchased a new position in shares of Adaptive Biotechnologies during the second quarter valued at about $5,346,000. Finally, Geode Capital Management LLC raised its stake in Adaptive Biotechnologies by 15.6% in the second quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock worth $37,461,000 after buying an additional 434,347 shares in the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ADPT shares. Guggenheim increased their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. BTIG Research upped their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Adaptive Biotechnologies Trading Down 5.3%

NASDAQ ADPT opened at $15.20 on Friday. Adaptive Biotechnologies Corporation has a 12 month low of $6.26 and a 12 month high of $20.76. The stock’s fifty day moving average price is $16.91 and its 200-day moving average price is $15.59. The stock has a market cap of $2.32 billion, a P/E ratio of -38.00 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. During the same quarter in the previous year, the firm earned ($0.23) EPS. Adaptive Biotechnologies’s quarterly revenue was up 51.0% compared to the same quarter last year. As a group, analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Chad M. Robins sold 124,998 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $15.59, for a total value of $1,948,718.82. Following the transaction, the chief executive officer owned 2,584,243 shares in the company, valued at approximately $40,288,348.37. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Robert Hershberg sold 22,968 shares of the firm’s stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $16.00, for a total transaction of $367,488.00. Following the sale, the director directly owned 46,722 shares of the company’s stock, valued at $747,552. This trade represents a 32.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 906,556 shares of company stock valued at $16,143,664. 6.40% of the stock is owned by company insiders.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.